Analysts Set Expectations for NMRA Q1 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Monday, March 3rd. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.44) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics’ Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.45) EPS.

NMRA has been the subject of a number of other research reports. HC Wainwright reduced their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 price target on shares of Neumora Therapeutics in a report on Tuesday. JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday. Finally, Bank of America decreased their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Neumora Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $11.50.

Neumora Therapeutics Stock Up 0.7 %

Shares of NASDAQ:NMRA opened at $1.41 on Wednesday. Neumora Therapeutics has a fifty-two week low of $1.35 and a fifty-two week high of $21.00. The firm’s 50-day simple moving average is $3.02 and its 200-day simple moving average is $8.81. The company has a market cap of $227.80 million, a price-to-earnings ratio of -0.75 and a beta of 2.50.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NMRA. Mirae Asset Global Investments Co. Ltd. acquired a new position in Neumora Therapeutics in the 4th quarter valued at about $61,000. PNC Financial Services Group Inc. acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at $64,000. Quantbot Technologies LP acquired a new position in Neumora Therapeutics in the fourth quarter valued at $92,000. PEAK6 LLC acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at about $117,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Neumora Therapeutics during the 4th quarter worth about $135,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.